melarsoprol
Small moleculeexperimental
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness. It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection and is known by patients as "fire in the veins". — Wikipedia
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00330148)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(N)nc(Nc2ccc([As]3SCC(CO)S3)cc2)n1- Mol. weight
- 398.35 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaMelarsoprol ↗
- ChEMBLCHEMBL166 ↗
Also known as
- arsobal
- arsobal
- arsobal
- melarsaprol
- melarsen b
- melarsopol
- melarsoprol
- melarsoprol
- melarsoprol
- melarsoprol
- melarsoprol
- melarsoprol
- mel b
- mel b
- rp 3854
- rp 3854
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00330148 | Phase 3 | Mar 1, 2001 | Epicentre, Government of France, Medecins Sans Frontieres, National Sleeping Sickness Control Program, Uganda |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epicentre | For profit | 1 | 1 | 1 | 2001 |
| Government of France | Government | 1 | 0 | 1 | 2001 |
| Medecins Sans Frontieres | Academic/Hospital | 1 | 0 | 1 | 2001 |
| National Sleeping Sickness Control Program, Uganda | Government | 1 | 0 | 1 | 2001 |
4 organizations
Page 1 / 1